Technical Analysis for EVAX - Evaxion Biotech A/S

Grade Last Price % Change Price Change
F 1.47 4.64% 0.07
EVAX closed down 10.25 percent on Wednesday, November 20, 2024, on 78 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 4.64%
Lower Bollinger Band Walk Weakness 4.64%
New 52 Week Low Weakness 4.64%
Wide Bands Range Expansion 4.64%
Lower Bollinger Band Touch Weakness 4.64%
Oversold Stochastic Weakness 4.64%
New Downtrend Bearish -6.08%
Calm After Storm Range Contraction -6.08%
Lower Bollinger Band Walk Weakness -6.08%
Wide Bands Range Expansion -6.08%

   Recent Intraday Alerts

Alert Time
Possible NR7 3 minutes ago
Possible Inside Day 3 minutes ago
Up 5% 39 minutes ago
60 Minute Opening Range Breakout about 1 hour ago
Up 3% about 1 hour ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Evaxion Biotech A/S Description

Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Artificial Intelligence Immunotherapy Surgery Cancer Immunotherapy Genomics Immunotherapies Non Small Cell Lung Cancer Medical Genetics Melanoma Vaccination Viral Disease Bladder Cancer Cancer Vaccine Bacterial Disease Treatment Of Various Cancers Viral Infections Hernia

Is EVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.55
52 Week Low 1.28
Average Volume 59,749
200-Day Moving Average 3.20
50-Day Moving Average 2.65
20-Day Moving Average 2.32
10-Day Moving Average 1.94
Average True Range 0.27
RSI (14) 23.08
ADX 27.75
+DI 9.43
-DI 32.22
Chandelier Exit (Long, 3 ATRs) 2.28
Chandelier Exit (Short, 3 ATRs) 2.10
Upper Bollinger Bands 3.33
Lower Bollinger Band 1.31
Percent B (%b) 0.04
BandWidth 87.02
MACD Line -0.33
MACD Signal Line -0.23
MACD Histogram -0.108
Fundamentals Value
Market Cap 6.74 Million
Num Shares 4.81 Million
EPS -9.50
Price-to-Earnings (P/E) Ratio -0.15
Price-to-Sales 0.00
Price-to-Book 7.59
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.87
Resistance 3 (R3) 1.88 1.73 1.79
Resistance 2 (R2) 1.73 1.61 1.73 1.76
Resistance 1 (R1) 1.57 1.54 1.50 1.56 1.74
Pivot Point 1.42 1.42 1.39 1.42 1.42
Support 1 (S1) 1.26 1.30 1.19 1.25 1.06
Support 2 (S2) 1.11 1.23 1.11 1.04
Support 3 (S3) 0.95 1.11 1.01
Support 4 (S4) 0.94